Key facts
- Truemeds’s last known valuation is $331.0M (Jul 2025).
- It has raised $113.2M; the latest was Later Stage VC ($64.0M) in Jul 2025.
- Notable investors include Accel, Peak XV Partners, Prosus Ventures, Indian Angel Network, InfoEdge Ventures — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Truemeds
- ·The full record, as it builds
Funding rounds
No funding rounds for Truemeds are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Truemeds
Operator of a telehealth platform intended to make healthcare accessible to every patient. The company's platform advises patients about substitute medicines offered by reputed pharmaceutical companies and recommends appropriate value medicines to customers with precise scientific matching and outcome history, enabling patients to choose the right medicine at an affordable price.
- Sector
- Healthcare
- HQ
- Mumbai, India
- Founded
- 2018
- Employees
- 3,000
- Website
- truemeds.in/
- Ownership
- Privately Held (backing)
Truemeds doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Truemeds shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Truemeds in its N-PORT filings yet. We sweep new filings monthly.